Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

Delayed Quote. Delayed  - 12/08 10:00:13 pm
62.42 USD   +0.94%
02:11p BRISTOL MYERS S : Announces Dividend Increase
01:27p Merck raises stakes in lung cancer as rivals close in
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
News SummaryMost relevantAll newsSector newsTweets

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2012 | 05:26am CET
   By Rumman Ahmed 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
02:11p BRISTOL MYERS SQUIBB : Announces Dividend Increase
01:27p Merck raises stakes in lung cancer as rivals close in
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
12/09 BRISTOL MYERS SQUIBB : Sprycel (dasatinib) Added to Standard Chemotherapy Demons..
12/09 BRISTOL MYERS SQUIBB : Announces 2.6% Quarterly Dividend Increase
12/08 BRISTOL-MYERS SQUIBB COMPANY : - U.S. Food and Drug Administration Lifts Partial..
12/07 BRISTOL MYERS SQUIBB : Announces Dividend Increase
12/07 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb in the Area of Dru..
12/07 BRISTOL MYERS SQUIBB : CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo n..
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
More news
News from SeekingAlpha
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/10 WEEK IN REVIEW : China Life Science Deals Total $550 Million
12/07 Bristol-Myers Squibb declares $0.40 dividend
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/07 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 7, 2017
Financials ($)
Sales 2017 20 634 M
EBIT 2017 5 598 M
Net income 2017 4 351 M
Debt 2017 295 M
Yield 2017 2,53%
P/E ratio 2017 24,05
P/E ratio 2018 20,93
EV / Sales 2017 4,97x
EV / Sales 2018 4,74x
Capitalization 102 B
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 63,8 $
Spread / Average Target 2,2%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559